'
Supriya
Lifescience hosted a conference call on Aug 14, 2025. During the call, the
company was represented by Dr. Satish Wagh, Executive Chairman & WTD; Dr.
Saloni Wagh, Managing Director; and Mr. Krishna Raghunathan, Chief Financial
Officer.
Key takeaways of the call
In Q1 FY26,
revenue declined on a YoY basis due to delays in the production, caused by
repair and maintenance work. However, management reaffirmed its guidance of
approximately 20% YoY revenue growth for FY26 and aims to achieve Rs 1,000
crore in revenue by FY27, with an EBITDA margin between 33% and 35%.
The company
expects H2 FY26 to be significantly stronger than H1 FY26. Management
attributes the revenue decline solely to production issues and does not
anticipate any demand-related challenges.
Growth is
expected to be driven by the introduction of new products and expansion into
newer therapies. Th...
Pleaselogin & subscribe to view the full report.
More Reports
-
(13-Jan-2026)
HCL Technologies
Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
-
(13-Jan-2026)
Tata Consultancy Services
Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
-
(12-Jan-2026)
Krishana Phoschem
Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
-
(11-Jan-2026)
Avenue Supermarts
Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026
|
|